In a preclinical study of melanoma, IDO inhibition in IDO-expressing B16 melanoma, but not wild-type melanoma, decreased the tumor size, while direct AhR inhibition decreased the tumor size in both IDO- and TDO-expressing tumors [17]. This evidence concerns the gene IDO1 and neoplasm.